Hengrui Pharma Wins First China Approval for Home-Grown Long-Acting Insulin AnalogTip Ranks·1 day ago, 09:38 AM01276-1.54%600276+1.41%
Nomura Cuts HENGRUI PHARMA TP to HKD82.18, Lowers FY2026 Revenue and Profit ForecastsAASTOCKS News·Jul 26 at 10:29 PM01276-1.54%600276+1.41%
Hengrui Wins NMPA Nod to Move Cervical Cancer Combo to First-Line UseTip Ranks·Jul 23 at 07:37 AM01276-1.54%600276+1.41%
Hengrui Pharma wins China approval for camrelizumab-famitinib combo as 1L cervical cancer treatmentPUBT·Jul 23 at 07:32 AM01276-1.54%600276+1.41%
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H (1276) Receives a Buy from Morgan StanleyTip Ranks·Jul 17 at 07:27 PM01276-1.54%600276+1.41%
IDEAYA shares ESMO 2026 data updates for darovasertib trials in uveal melanomaPUBT·Jul 17 at 08:00 AMIDYA+0.37%01276-1.54%
Hanx Biopharmaceuticals files HKEX next-day disclosure return on share repurchase cancellationPUBT·Jul 16 at 05:27 AM03378+6.00%
IDEAYA Biosciences Announces ESMO 2026 Presentations for Darovasertib and IDE849 Clinical Programs | IDYA Stock NewsStockTitan·Jul 17 at 12:00 AMIDYA+0.37%600276+1.41%
China’s Hengrui Pharma Is Hit by Third Delay in US Approval for Liver Cancer DrugYicai·Jul 10 at 07:53 AM01276-1.54%600276+1.41%
UBS: Positive Clinical Data for HENGRUI PHARMA 's Weight-loss Drug HRS-7535; Attractive Valuation, Reiterates BuyAASTOCKS News·Jul 9 at 01:36 AM600276+1.41%01276-1.54%
China’s biotech boom: RAS-targeted drugs challenge US dominanceSCMP·Jul 8 at 03:05 AM01276-1.54%600276+1.41%
